Clinical trial · Interventional
AI Chatbot for Prostate Radiation Therapy Patient Education
Clinical Evaluation of Large Language Model (LLM) Methods to Support Prostate Cancer Radiation Therapy Patient Education
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
This study will evaluate whether an artificial intelligence chatbot can help patients better understand radiation therapy for localized prostate cancer. Participants will be adults with prostate cancer who are planning definitive radiation therapy at Brigham and Women's Hospital. All participants will receive standard radiation therapy education and clinician-led discussions as part of routine care. In addition, participants will interact with an educational chatbot about prostate cancer radiation therapy. The chatbot is designed to provide plain-language information about treatment logistics, preparation, possible side effects, follow-up, and when to contact the care team. The chatbot will not provide diagnosis, treatment recommendations, individualized medical advice, or replace conversations with clinicians. Participants will complete questionnaires before and after using the chatbot. The study will measure changes in patient understanding, confidence in managing symptoms, usability of the chatbot, and safety-related concerns identified during clinician review of chatbot responses.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AI Educational Chatbot | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- AI Chatbot Educational Intervention
- description
- Participants will complete baseline questionnaires, interact with the LLM-based prostate radiation education chatbot, and then complete post-intervention questionnaires. The chatbot is used in addition to standard radiation therapy education and clinician-led discussions.
- interventionNames
- Other: AI Educational Chatbot
Primary outcomes (1)
- measure
- Change in PROMIS Self-Efficacy for Managing Symptoms Score
- timeFrame
- Baseline before chatbot interaction to immediately after chatbot interaction during the same study session
- description
- Within-participant change in symptom self-efficacy will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Symptoms instrument. Scores are reported as PROMIS T-scores, with a mean of 50 and standard deviation of 10 in the reference population. Higher scores indicate greater confidence in managing symptoms, which is a better outcome. There is no fixed minimum or maximum T-score, although typical PROMIS T-scores generally range from approximately 20 to 80.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Current diagnosis of prostate cancer * Planning to receive definitive prostate cancer radiation therapy at Brigham and Women's Hospital Department of Radiation Oncology * English-speaking * Ability to understand and willingness to provide informed consent Exclusion Criteria: * Adults unable to consent independently * Individuals who are not yet adults * Prisoners
References
Publications (0)
Data not yet available